Amgen UK’s Chris Fox: Up for the Challenge
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
Address: Unit 6 Regents Drive,
Low Prudhoe Industrial Estate, Northumberland.
NE42 6PX.,United Kingdom
Tel: +44 (0) 1661 833 693
Web: www.scmpharma.com
SCM Pharma is a UK-based contract development and manufacturing organisation (CDMO) that develops and delivers novel, difficult and dangerous drugs on behalf of its clients. The company works with clients progressing drugs through the pre-clinical formulation stage, clinical trials and others that require low volume commercial supply of niche licensed products.
Privately-owned, SCM Pharma’s corporate HQ and MHRA-licensed manufacturing facilities are located in North East England with recently acquired additional laboratory space within the University of Sunderland’s state-of-the-art £8.5m science complex. Its clients include top 10 big pharma, speciality pharmaceutical companies, small biotech firms, virtual companies, public sector bodies and academic institutions from across Europe and North America.
With specific expertise in custom formulation, complex cGMP sterile manufacturing and aseptic filling, the award-winning CDMO is able to handle 14C radiolabeled compounds and potent products including cytotoxics. Its specialist offerings include –
• Process development
• Formulation development
• Aseptic processing (using isolator technology)
• Non-aseptic processing followed by terminal sterilisation
• GMP filling of 14C radiolabeled compounds
• Fill/¬finish of highly potent products including cytotoxic and cytostatic formulations
• Drug/medical device fi¬lling and assembly
• In-house testing including sterility, endotoxin, microbiology and analytical chemistry
• ICH stability testing
• Clinical packaging and distribution
• QP release
SCM Pharma can fill liquids, gels and powders into a range of final dosage forms including ampoules, vials, cartridges, syringes, bottles.
Christine (Chris) Fox, VP general manager UK and Ireland at Amgen discusses the rationale behind taking on the management of a UK affiliate in challenging times and the specificities of…
A spinout from the Roslin Institute that created Dolly the Sheep, Roslin CT is a cell and gene therapy CDMO, with a unique positioning in the field today. Its CEO,…
Jonny Ohlson, founder & CEO of Touchlight, discusses the genetic medicine revolution and the role of Touchlight in disrupting the field with its revolutionary DNA technology. You founded Touchlight Genetics…
Dr. Geoffrey Guy, chairman and founder of cannabinoid medicine pioneer, GW Pharma, outlines the potential benefits that Brexit could bring to the UK’s life sciences industry and the evolution of…
KaNDy Therapeutics, a UK-based biotech has raised £25 million to finance the Phase 2b trial of their breakthrough product in Women’s Health. Our investors and the KaNDy management team are united…
Sterling Pharma Solutions is a rapidly growing GMP contract API manufacturer based out of Dudley, Cramlington in the Northeast of England. The company was set up in its current structure…
Offering genomic sequencing and analysis, Congenica operates in the exciting world of genomic diagnosis, with a particular focus on rare diseases. Its CEO David Atkins describes the potential of Congenica’s…
Sean Richardson discusses Alexion’s focus on rare and ultra-rare diseases, the level of support for these therapies from the UK government, awareness raising, diagnostics, and his future priorities. …
With over 30 years of experience in the life sciences industry, Angela McFarlane explains why the UK will not be removed from its position in the top 3 for new…
For Ipsen, the UK is one of three global hubs, with manufacturing in Wales in which it is continuously investing, as well as large-scale R&D activities near Oxford. Ipsen’s general…
Brexit, Brexit, Brexit. It’s all anyone can talk about and yet nobody can tell you with certainty what to expect. As the UK’s impending withdrawal from the European Union looms…
Professor David Garway-Heath, a specialist in glaucoma, talks with us about the screening devices of the future, low awareness of glaucoma as a chronic disease and collaboration in training and…
See our Cookie Privacy Policy Here
